# US 2009/0269283 A1 · Method and product for locating an internal bleeding site

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269283 A1
- Document ID: US20090269283A1
- Status: Published application
- Kind: A1
- Application number: 12/348,652
- Filed: 2009-01-05
- Published: 2009-10-29
- Earliest claimed: 2004-07-29
- Assignees: Cold Spring Diagnostics, Inc.
- Inventors: Seth Karp; Evan Garfein; John V. Frangioni; Shunsuke Onishi
- Web page: https://patentgrep.com/patent/US20090269283A1

## CPC

- A61K 38/363: {Fibrinogen}
- A61K 38/36: Blood coagulation or fibrinolysis factors
- A61K 38/37: Factors VIII
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 38/4853: {Kallikrein (3.4.21.34 or 3.4.21.35)}
- A61K 49/0002: {General or multifunctional contrast agents, e.g. chelated agents}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0034: {Indocyanine green, i.e. ICG, cardiogreen}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 49/14: Peptides, e.g. proteins
- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- B82Y 10/00: Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

A method is provided for localizing an internal bleeding site whereby a protein or other factor involved in the clotting process is complexed to an imaging agent and injected into a patient believed to be at risk of internal bleeding. A clot in the patient will naturally accumulate a certain concentration of the injected complex, and within a short period of time the concentration becomes sufficient to be detected by an imaging apparatus. The imaging contrast agent may, for example, be an MRI contrast agent, a CT contrast agent, a PET agent, or a fluorescent substance.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for localizing an internal bleeding site in the body of a mammal believed to be at risk of internal bleeding, said method comprising:
introducing into the circulatory system of the mammal a solution comprising a clotting factor that is capable of contributing to clot formation, and a contrast agent complexed to said clotting factor, wherein said contrast agent comprises a fluorescent substance;
permitting time to pass for at least some of the clotting factor in the solution to become localized to the bleeding site to participate in clot formation;
scanning the exterior portion of the body of the mammal near a suspected bleeding site using a fluoroscope to detect the contrast-agent-labeled clotting factor so as to determine a location of the bleeding site based upon a concentration of the contrast agent complexed to the clotting factor.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the fluorescent substance comprises indocyanine green, iodocyanine green, IRDye78, IRDye80, IRDye38, IRDye40, IRDye41, IRDye700, IRDye800, Cy7, IR-786, DRAQ5NO, quantum dots, and analogs thereof.

### Claim 23 (depends on 21)

The method according to claim 21, wherein the clotting factor comprises any protein shown to localize to an area of a clot.

### Claim 24 (depends on 21)

The method according to claim 21, wherein the clotting factor comprises any protein shown to localize to an area of a clot.

### Claim 25 (depends on 21)

The method according to claim 21, wherein the clotting factor comprises at least one of platelets, Factors I, Ia, II, IIa, V, Va, VII, VIIa, VIII, VIIIa, IX, IXa, X, Xa, XI, XIa, XII, XIIa, XIII, XIIIa, fibrinogen, fibrin, fibronectin, von Willebrand's factor, vinculin, vitronectin, Factor VIIIa component peptides, Factor VIIIb component peptides, ADP, serotonin, platelet factor 4, betathromboglobulin, high-molecular weight kininogen, kallikrein, prekallikrein and antithrombin III.

### Claim 26 (depends on 21)

The method according to claim 21, wherein the bleeding site is located in the colon.

### Claim 27 (depends on 21)

The method according to claim 21, wherein the bleeding site is located in the small intestine.

### Claim 28 (depends on 21)

The method according to claim 21, wherein the bleeding site is located in the stomach.

### Claim 29 (depends on 21)

The method according to claim 21, wherein the bleeding site is located in the esophagus.
